Sanjay Dixit
Endocrinology, Diabetes & Metabolism · Butler, PANPI 1194803122
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 76.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $29,288 and has fallen 99.9% since, to $40 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $134.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$32K
- Sanofi-aventis U.S. LLC$7K
- Lilly USA, LLC$737
- AstraZeneca$510
- Cequr Corporation$224
- Boehringer Ingelheim$198
- plus $1K from 22 others
What the payments were for
- Consulting fees$8,43020%
- Speaking & faculty fees$23,57957%
- Travel & lodging$3,2258%
- Food & beverage$6,13715%
- Education$2141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 126 | $31,853 |
| Sanofi-aventis U.S. LLC | 23 | $6,608 |
| Lilly USA, LLC | 46 | $737 |
| AstraZeneca(2 entities) | 17 | $510 |
| Cequr Corporation | 1 | $224 |
| Boehringer Ingelheim | 12 | $198 |
| BD | 8 | $185 |
| Johnson & Johnson | 7 | $113 |
| AbbVie | 5 | $100 |
| Merck | 7 | $98 |
| IBSA Pharma Inc. | 5 | $95 |
| Amgen | 5 | $90 |
| Insulet Corporation | 6 | $87 |
| Bayer | 5 | $81 |
| Abbott | 5 | $77 |
| Amarin Pharma, Inc. | 5 | $77 |
| Tandem Diabetes Care, Inc. | 4 | $68 |
| Amneal Pharmaceuticals LLC | 3 | $55 |
| Dexcom, Inc. | 4 | $52 |
| Corcept Therapeutics | 3 | $48 |
| Shire North American Group Inc | 3 | $46 |
| Phadia US Inc. | 1 | $44 |
| Medtronic | 3 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Valeritas, Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $18 |
| Embecta Corp. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$17,967
- Ozempic$12,095
- DISEASE STATE$6,282
- FARXIGA$271
- CeQur Simplicity$224
How this compares
$41,585 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Other endocrinology, diabetes & metabolism in Butler
- Emily MartinButler$227K
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.